These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 30767720)
1. Iatrogenic CNS demyelination in the era of modern biologics. Kumar N; Abboud H Mult Scler; 2019 Jul; 25(8):1079-1085. PubMed ID: 30767720 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic. Kelly H; Johnson J; Jakubecz C; Serra A; Abboud H J Neuroimmunol; 2022 Sep; 370():577928. PubMed ID: 35853358 [TBL] [Abstract][Full Text] [Related]
3. Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. Kunchok A; Aksamit AJ; Davis JM; Kantarci OH; Keegan BM; Pittock SJ; Weinshenker BG; McKeon A JAMA Neurol; 2020 Aug; 77(8):937-946. PubMed ID: 32421186 [TBL] [Abstract][Full Text] [Related]
4. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Karussis D; Petrou P Autoimmun Rev; 2014 Mar; 13(3):215-24. PubMed ID: 24514081 [TBL] [Abstract][Full Text] [Related]
5. Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese. Chan KH; Lee R; Lee JC; Tse AC; Pang SY; Lau GK; Teo KC; Ho PW J Neuroimmunol; 2013 Sep; 262(1-2):100-5. PubMed ID: 23838529 [TBL] [Abstract][Full Text] [Related]
6. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Pérez-De-Lis M; Retamozo S; Flores-Chávez A; Kostov B; Perez-Alvarez R; Brito-Zerón P; Ramos-Casals M Expert Opin Drug Saf; 2017 Nov; 16(11):1255-1271. PubMed ID: 28854831 [TBL] [Abstract][Full Text] [Related]
8. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. Karussis D J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923 [TBL] [Abstract][Full Text] [Related]
9. Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha Inhibitor. Chey SY; Kermode AG Mult Scler J Exp Transl Clin; 2022; 8(1):20552173211070750. PubMed ID: 35024163 [TBL] [Abstract][Full Text] [Related]
14. Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy. Cortese R; Prosperini L; Stasolla A; Haggiag S; Villani V; Simone IL; Gasperini C; Tortorella C J Neurol; 2021 Aug; 268(8):2895-2899. PubMed ID: 33611609 [TBL] [Abstract][Full Text] [Related]
15. Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature. Oliveira MCB; de Brito MH; Simabukuro MM Front Neurol; 2020; 11():538695. PubMed ID: 33362680 [TBL] [Abstract][Full Text] [Related]
16. The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports. Bellinvia A; Pastò L; Razzolini L; Fratangelo R; Prestipino E; Fonderico M; Tudisco L; Amato MP Mult Scler Relat Disord; 2019 Aug; 33():51-54. PubMed ID: 31152967 [TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system]. Yang Y; Wu WP; Huang DH; Wu L Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(43):3032-5. PubMed ID: 23328372 [TBL] [Abstract][Full Text] [Related]
19. Type 2 Inflammatory Responses in Autoimmune Demyelination of the Central Nervous System: Recent Advances. Costanza M J Immunol Res; 2019; 2019():4204512. PubMed ID: 31205957 [TBL] [Abstract][Full Text] [Related]
20. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Singh S; Kumar N; Loftus EV; Kane SV Inflamm Bowel Dis; 2013; 19(4):864-72. PubMed ID: 22552994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]